<DOC>
	<DOCNO>NCT00120835</DOCNO>
	<brief_summary>This study conduct treatment-naive patient ( previous hepatitis C treatment ) evaluate safety valopicitabine ( NM283 ) alone together pegylated interferon , drug approve Food Drug Administration treatment hepatitis C infection . This study also evaluate ability valopicitabine decrease amount hepatitis C virus body . The result patient take valopicitabine alone compare result patient take valopicitabine together pegylated interferon .</brief_summary>
	<brief_title>Valopicitabine When Administered Alone Combination With Interferon Treatment-Naive Patients With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Documented clinical history compatible genotype1 , chronic hepatitis C infection Treatmentnaive ( patient receive previous therapy hepatitis C viral infection ) Other protocoldefined inclusion criterion may apply . Patient pregnant Patient coinfected hepatitis B HIV Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Genotype-1</keyword>
	<keyword>Treatment-Naive</keyword>
</DOC>